The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), Johnson & Johnson (Gold), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | GLORA trial: lisaftoclax plus BTKi in previously treated CLL
In this video, Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, introduces the GLORA trial (NCT06104566). This Phase III study will investigate whether adding lisaftoclax to a BTK inhibitor (BTKi) improves outcomes in patients with previously treated chronic lymphocytic leukemia (CLL) and residual disease after prolonged BTKi treatment. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
